In this solo presentation Dr. Dino Prado, founder of Envita Medical Centers, warns that a substantial proportion of cancers (≈49% according to a 2020 study) evolve rapidly through genomic catastrophes such as chromothripsis and copy‑number amplifications, which can be accelerated by standard high‑dose chemotherapy. He critiques the one‑size‑fits‑all NCCN guideline approach that relies on limited biopsies, tumor markers, and imaging, arguing that it often misses these aggressive drivers. Prado advocates deep, comprehensive molecular profiling—including DNA next‑generation sequencing, RNA transcriptomics, and immune spatial biology—to detect chromothripsis, gene‑copy gains, inflammatory signaling, and immune evasion. He explains how inflammation fuels tumor growth and how a compromised immune system permits resistance. With precise molecular and immune data, he outlines targeted precision strategies such as genetically targeted fractionated chemotherapy (GTFC), chemo‑immuno‑precision injections, autologous adoptive immunotherapy, and cancer‑cell vaccines, emphasizing micro‑dose delivery and direct tumor targeting. The talk concludes with concrete questions patients should ask their doctors about testing and treatment, a call to seek physicians who employ these advanced diagnostics, and an appeal for viewers to subscribe and spread precision‑oncology education.
Chapters
What if I told you some cancers can level up faster than the drug you're taking? Not in years, in weeks. And if you don't test the right way and follow a targeted treatment, you may never see it coming. And when this presents, the prognosis is worse because the danger is not always in the new mutation. It's something most doctors were never taught to look for. This is called more gene copies. And sometimes extra DNA acts like a cheat code so cancer can grow faster and adapt faster. In this episode, I'm going to explain something so important, affecting an estimated 49% of the cancer patients worldwide. And I'll show you how to identify it and more importantly, how to treat aggressive cancers. And again, this is so important because most doctors are not testing and in fact are causing it, oftentimes with high dose, maximum therapeutic chemotherapy that's not targeted for the patient. So we're going to get into that today. The solution isn't fear, and it's knowing exactly how to test and how to target this. And clarity comes from deep testing and technology that can help you. I'm Dr. Dino Prado, founder of Envita medical centers. My team and I have been blessed to help many thousands of patients over the years that have failed the top cancer hospitals across the United States. Make sure you're always working with a doctor before you change anything. Now let's talk about the standard of care and some of the problems of what I call one size fits all cancer treatment or the NCCNN guidelines, National comprehensive cancer network guidelines. So you're using maybe a biopsy, a tumor marker, and imaging, which is giving you maybe 24 markers. And if you're lucky, you might get some DN biomarkers that give you some targets. But this is often a one size fits all model. So all cancer patients with the same type and stage are relatively given the same protocol across the United States and around the world. The problem is two cancers of the same type are very different. They have heterogeneicity. And when you look at what we look at, which is a thousand plus markers, DNA, RNA transcriptomics, immune spatial profiling, and immune spatial biology, we start to see a big difference in the targets. And this becomes very important with aggressive cancers. Many patients never get deep, comprehensive tests that shows you what the tumor is really doing and why this matters. It's because tumors don't just grow, they adapt and they level up fast. Cancer cells can get messy mutations, and sometimes their DNA disaster event is called chromothripsis, meaning the chromosomes get blown up, breaks into many pieces and gets stitched back together in the wrong way, Resembling a jumbled DNA mess. Random order leading to thousands of rearrangements. See, this is so important because if this is going on, it changes the game on cancer. And when that stitching is messy, Something big can happen. You can get copy number changes. That means that the tumor can end up with many more copies of growth genes than normal. And so normal cells usually have like two copies. Some cancer cells can get 10 to 50 or even more. And when a cancer cell has extra copies of these growth genes, it's like the cancer turns up the volume. More copies means faster growth, Better survival for the cancer cell, More drug resistance. And that's why some patients feel like all the work. Why can I stop this disease? And it just keeps growing. That's not always because your body failed. It can be because the tumor is changing its playbook. Now, here's the part most doctors miss. Chromothripsis. This phenomenon involving this catastrophic shattering and chaotic reassembly of these chromosomes can be induced by chemotherapy itself. The standard of care, high dose chemotherapy, we have found in our clinical experience. 90% of the patients that come to us are on the wrong chemotherapy selection. So they are not only doing iv chemo, which very little makes it to the tumor, let's say less than 5%. And we're being generous, it could be 1 to 2% is actually making it to the tumor. Now, the rest is damaging your immune system. It's going to your organs, your central nervous system. But it also could be pushing this phenomenon of chromothripsis. This is a big deal. So research indicates that these treatments can trigger the DNA damage, and when improperly repaired, it leads to aggressive drug resistant cancers and malignancies. And I believe very much this is what we've been fighting two and a half decades. This is why everyone needs deep testing and targeting before they start care. In my clinical experience, because the one size fits all model of chemotherapy Is outdated, In my clinical opinion, when cancer grows fast, it needs fuel. The 2020 study, analyzing 28 cancer types found this aggressive nature in 49% of cancer cases. And one of the biggest fuels is inflammation. Inflammation is not just swelling. It's the signal. And it's that signal system that's stuck and pushing the cancer to dangerous growth signals. And it can help that cancer grow faster. H better resist treatments. And so inflammatory survival signals Are known to create resistant drivers. So think of it like this. The tumor is on fire. The gene copies are changing and spreading. But inflammation Is like the gasoline that's pushing the cancer. Now here's the part that matters the most. The immune system. It's the first and last defense against cancer. And if the immune system is strong and recognizes the cancer and gets rid of it, we can avoid a lot of this. If the immune system is blocked, confused, and exhausted, which we see in a lot of patients, the tumors get more room to grow. And that's, that's why in this episode, it's not just about DNA. And a lot of people talk about metabolomics and glucose, and yes, that plays a role in slowing down the feeding of cancer and its metabolic pathway. But here we're talking about how these mutations can grow so quickly, and we need to deal with them so that we can help a patient respond better. It's about the whole battlefield. The tumor growth signals, the immune system readiness, the inflammation that feeds resistance, and the body's ability to tolerate treatment long enough to win. Because here's the hard truth. Even the best treatment plan can fail if you can't stay ahead of this and remove this gene accelerated model. So what's the solution? The solution is to stop treating cancer as a one size fits all and start using the targeted precision model. I want to break this down because it's very important in chromothripsis. First of all, we can test for chromothripsis using DNA next generation sequencing and specific biomarkers done through bioinformatics. We can look at these amplifications, we can see that this is occurring in a patient, these massive clusters of genomic rearrangements. And this matters because we can look at the copies in the test and we can see if the tumor is leveling up and it's getting resistant. And we can identify that. And now this helps us to dial in treatment even more. The DNA tells us what parts are present. The RNA tells us what parts are actually turned on, so we can see the pathway. So two tumors can look the same in the DNA, but can be totally different, Because RNA helps us see what's driving the tumor right now. And yes, this is important to chromothripsis Because RNA sequencing can show the consequence of these rearrangements, like gene fusion, abnormal gene expression, and novel transcripts. Here's where immune profiling comes in. What's suppressing the immune system? What's blocking it from doing its work? Because the immune system is always a first and last defense against cancer, and it gets us out of the guesswork and helps us to shut down the cancer. And when we look at immune spatial biology. This answers one of the most important questions. Are the immune cells present? What are they doing? And how can we turn a cold tumor hot and get rid of it? It might be stuck, it might be resistant. A tumor can look immune active on paper, but in a spatial biology sense, the immune cells may be locked out. That changes the strategy. Understanding spatial arch of chromothriptic tumors helps us to develop targets more effective immunotherapies. Overcoming resistance by identifying areas with low immune infiltration and high heterogenicity. Meaning it's very, very different. Very mutational. Spatial profiling helps identify where these combinations of the treatment might be more effective. And gives us an ability to treat the patient with precision. Now here's why this testing matters for super fast cancers. Because when cancer adapts fast, you must move smart. Not just hard, but smart. You must protect and strength. These three things to stop that growth of this cancer. Number one, immune competence so your body can recognize and fight the cancer. Your immune system is critical inflammation control so your tumor is not swimming. And growth signaling. It's not just growing with signals that push resistance treatment tolerance so you can stay in the fight long enough to win. That's what targeting and precision is all about. And comprehensive testing gives us the target. So we get out of the guesswork and into the targets that patients need. It helps us to avoid that guesswork and overdosing and wrong treatment, causing this hyper growth that we see. And chromothripsis patients, these fast growing, leveling up cancers, it helps us to understand why something's working or not working. It helps us to plan the right combinations at the right micro doses, deliver them direct to tumor or rebuild the immune system. See, the goal here is to stop the condition from evolving in the first place. And yes, when you have targets, we can do that. So in things that we use, like gtfc, genetically targeted fractionated chemotherapy, or chemoimmunoprecision injections, or autoglous adoptive immunotherapy, all the different things we do, from cancer cell vaccines to targets to microdos, all of it targeting the body helps us to attack this straight on. So here's a key takeaway. If the standard of care gives you a small snapshot, you may be missing the real driver. But if you have the right testing, rna, DNA, immune profiling, immunospatial biology, biomarkers and the transcriptomics, you now can see the battlefield and you can get precision. And you can attack these aggressive cancers in a way that you couldn't before. So here's the questions you want to ask your doctor Because I think this is important to kind of bringing it all together for you so you can actually put this to work. Do I have a fast growing cancer? Have you tested the DNA and next generation sequencing to see if I have chromothripsis or an aggressive pattern of cancer going on through the proper bioinformatics? Have you tested my RNA transcriptomics to uncover the oncogenes that are amplifying this growth and can we shut it down? Have you tested my immune system, my immune profiling and spatial biology so we can target my tumor so it doesn't continue to grow? These are great questions because we want to stop that proliferation and differentiation. We want to shut it down. These are the key questions you want to ask. And if your doctor says, I don't know, we don't do that, we don't have the answers here, then your job is to find a doctor that does because that's what you need to do. If you have aggressive cancers, and we know where these aggressive cancers typically are, it can be in almost any cancer type. But we see them in the dirty cancers, these complex ones. That's why this episode, I believe is so important. I hope you found it helpful. Over 90% of you are watching but not subscribing and I ask you to subscribe so you can help us get precision oncology around the world. It changes the way doctors think, patients think. It changes the whole ecosystem so we can change healthcare to not be a one size fits all but targeted. And the way YouTube algorithms work is the more you subscribe and share, the more they push this out to people so people can become educated. I hope you found this helpful and it gave you an idea of aggressive cancers and the right way to approach them. May the Lord bless you on your journey to healing. Sam.
